Citius Pharmaceuticals Inc
(STU:47N)
€
0.581
-0.0155 (-2.6%)
Market Cap: 102.78 Mil
Enterprise Value: 91.39 Mil
PE Ratio: 0
PB Ratio: 1.22
GF Score: 40/100 - Citius Pharmaceuticals Inc at Sidoti & Company January Micro-Cap Virtual Conference TranscriptJan 18, 2023
- Citius Pharmaceuticals Inc at ThinkEquity Conference TranscriptOct 26, 2022
- Citius Pharmaceuticals Inc at Dawson James Small Cap Growth Conference TranscriptOct 12, 2022
- Citius Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Citius Pharmaceuticals Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 20, 2022
- Citius Pharmaceuticals Inc at Benzinga Virtual Global Small Cap Conference TranscriptMay 13, 2021
- Citius Pharmaceuticals Inc Corporate Analyst Meeting TranscriptDec 06, 2020
- Citius Pharmaceuticals Inc CEORoadshow Interview with Leonard Mazur TranscriptJul 10, 2020
- Citius Pharmaceuticals Inc at Noble Capital Markets Small and Microcap Investor Conference TranscriptFeb 16, 2020
Citius Pharmaceuticals Inc at Benzinga Virtual Global Small Cap Conference Transcript
May 13, 2021 / 05:50PM GMT
Release Date Price:
€1.65
(-7.82%)
Spencer Israel
Benzinga - Executive Producer, BenzingaTV
All right. Let's put on our next speaker here. Myron Holubiak is the President and CEO at Citius Pharmaceuticals. If the chat -- if social media chat is any indication, we seem to have a lot of people that are very interested in this company.
So, Myron, good afternoon. Good to see you.
Myron Holubiak
Citius Pharmaceuticals, Inc. - President & CEO
Good to see you, Spencer. Good catching up with you too.
Spencer Israel
Benzinga - Executive Producer, BenzingaTV
Yes, good catching up. All right. Let's go ahead and share your screen. I see it up there. There we go. I'm going to turn the floor over to you. Tell us about Citius.
Myron Holubiak
Citius Pharmaceuticals, Inc. - President & CEO
Thanks, Spencer. Thanks very much. I'll put up the standard disclaimer statement, but there's -- as you know, I've highlighted some things. So please, if anybody is interested in investing in Citius, we strongly
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)